Another ongoing therapeutic strategy under study concerns the conversion of classic galactosemia into GALK1 deficiency, a milder form of galactosemia in which patients do not accumulate Gal-1-P. The gene discussed is GAL; the disease is hyperinsulinemic hypoglycemia, familial, 4.